Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120

Journal of Infectious Diseases

Volumn 183, Issue 4, 2001, Pages 563-570

  Corey, Lawrence ^a   Mulligan, Mark ^b   Goepfert, Paul ^b   Sabbaj, Stephanie ^b   Clements Mann, Mary Lou ^c   Harrow, Clayton ^c   Schwartz, David ^c   Dolin, Raphael ^d   Evans, Thomas ^d   Keefer, Michael ^d   Belshe, Robert ^e   Gorse, Geoffrey ^e   Frey, Sharon ^e   McElrath, Julie ^a   Graham, Barney ^f   Wright, Peter ^f   Spearman, Paul ^f   Weinhold, Kent ^g   Montefiori, David ^g   Greenberg, Michael ^g   Klein, Michel ^h   El Habib, Raphaelle ^h   Excler, John Louis ^h   Duliege, Anne Marie ⁱ   Stablein, Donald ^j   Wolff, Mark ^j   Smith, Carol ^j   Grabowsky, Mark ^k   Savarese, Barbara ^k   Walker, Mary Clare ^k   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Lab Pasteur Merieux Connaught   (France)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j EMMES CORPORATION   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS INFECTION;

AIDS VACCINES; AVIPOXVIRUS; DOUBLE-BLIND METHOD; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV PROTEASE; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SYNTHETIC;

EID: 0035865873     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318523     Document Type: Article

References (45)

1. HIV-1 vaccine-induced immune responses which correlate with protection from SH1V infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
2. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
3. Progress in the development of an HIV-1 vaccine
4. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
5. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
6. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein rgp120, a randomized, double-blind trial
7. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine
8. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
9. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
10. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer
11. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
12. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
13. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting
14. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with gp160 in vaccinia-naive adults
15. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene
16. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
17. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immuno-deficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
18. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
19. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein
20. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial
21. Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen
22. SF2 recombinant gp120, or both vaccines in seronegative adults
23. Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Cytotoxic T cells
24. Nonreplication vaccinia vector efficiently expresses recombinant genes
25. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
26. Recombinant fowlpox virus including protective immunity in non-avian species
27. Fowlpox virus as a vector in non-avian species
28. Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowlpox viruses
29. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
30. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
31. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
32. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
33. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus
34. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
35. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
36. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
37. Immunisation with canarypox virus expressing rabies glycoprotein
38. + cytotoxic T lymphocyte responses in seronegative volunteers
39. Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay
40. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
41. + cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys
42. + memory T cells
43. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
44. Neutralization of a clade B primary isolate by sera from HIV uninfected recipients of candidate AIDS vaccines
45. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV